Literature DB >> 679973

Positive chronotropic and inotropic effects of angiotensin II in the dog heart.

M Kobayashi, Y Furukawa, S Chiba.   

Abstract

The effects of angiotensin II on sinus rate and atrial contractility were investigated in 17 isolated canine atria and 5 isolated paced ventricular preparations perfused with arterial blood conducted from a heparinized donor dog. When angiotensin II was injected into the cannulated sinus node artery, positive chronotropic responses were dose-dependently produced starting from the 0.01 microgram dose although inotropic responses to angiotensin II were not consistently induced. Angiotensin II produced a similar inotropic response pattern in the paced ventricular preparation. Moreover, when angiotensin II was given into the jugular vein of the donor dog, similar positive chronotropic and inotropic responses were also shown in the isolated atrium. Angiotensin II-induced positive chronotropic and slight inotropic effects were not influenced by treatment with the beta-adrenoceptor blocking agents, propranolol and carteolol, but significantly suppressed by saralasin which has been reported to be a competitive antagonist of angiotensin II. From these results, it is suggested that angiotensin II induced a positive chronotropic and slight positive inotropic effect via angiotensin II receptors in the dog heart.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679973     DOI: 10.1016/0014-2999(78)90249-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

Review 1.  Angiotensin II-receptor antagonist in the treatment of hypertension.

Authors:  Massimo Volpe; Giuliano Tocci; Erika Pagannone
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

2.  Positive chronotropic activity of angiotensin II in the pithed normotensive rat is primarily due to activation of cardiac beta 1-adrenoceptors.

Authors:  J T Knape; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

Review 3.  Cardiac alpha(1)-adrenoceptors that regulate contractile function: subtypes and subcellular signal transduction mechanisms.

Authors:  M Endoh
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

4.  Field-stimulus response of guinea-pig atria as influenced by the peptides angiotensin, bradykinin, and substance P.

Authors:  H Iven; R Pursche; G Zetler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-05       Impact factor: 3.000

5.  Characterization of an angiotensin-II-activated chloride current in rabbit sino-atrial cells.

Authors:  J Bescond; P Bois; J Petit-Jacques; J Lenfant
Journal:  J Membr Biol       Date:  1994-06       Impact factor: 1.843

6.  Influence of angiotensin converting enzyme inhibition on pump function and cardiac contractility in patients with chronic congestive heart failure.

Authors:  L H Baur; J J Schipperheyn; J Baan; A van der Laarse; B Buis; E E van der Wall; V Manger Cats; A D van Dijk; J A Blokland; M Frölich
Journal:  Br Heart J       Date:  1991-03

7.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 8.  [The renin-angiotensin system in cardiovascular diseases].

Authors:  C Unterberg; H Kreuzer; A B Buchwald
Journal:  Med Klin (Munich)       Date:  1998-07-15

9.  Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon.

Authors:  B D Hoit; Y Shao; A Kinoshita; M Gabel; A Husain; R A Walsh
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

Authors:  J P van Kats; L M Sassen; A H Danser; M P Polak; L K Soei; F H Derkx; M A Schalekamp; P D Verdouw
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.